Cochrane · systematic review · CD005184
Creatine and creatine analogues in hypertension and cardiovascular disease
Horjus, DL, Oudman, I, van Montfrans, GA, et al. · Cochrane Database of Systematic Reviews · 2011 · Cochrane Library
HypertensionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Effects of creatine and creatine analogues on ejection fraction in patients with heart failure
Population: patients with heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Creatine phosphate 1g/day | no estimate extracted | 1 study · 13 participants | Low |
Creatine 20g/day for 6 weeks | no estimate extracted | 1 study · 13 participants | Low |
Creatine 20g/day for 10 days | no estimate extracted | 1 study · 17 participants | Low |
Creatinine phosphate 1g/day for 6 months | no estimate extracted | 1 study · 79 participants | Low |
Creatinine phosphate 1g/day for 3 months | no estimate extracted | 1 study · 88 participants | Low |